Trial Outcomes & Findings for Efficacy of the Quell Wearable Device for Fibromyalgia (NCT NCT03714425)

NCT ID: NCT03714425

Last Updated: 2022-08-15

Results Overview

The questionnaire reflects a patient's belief about the efficacy of treatment. The Patients' Global Impression of Change (PGIC) is a 7-point scale (1-7) depicting a patient's rating of overall improvement. Patients rate their change as 1="very much improved," 2="much improved," 3="minimally improved," 4="no change," 5="minimally worse," 6="much worse," or 7="very much worse." Lower values represent a better outcome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

119 participants

Primary outcome timeframe

3 months

Results posted on

2022-08-15

Participant Flow

Participant milestones

Participant milestones
Measure
High Frequency Device
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Overall Study
STARTED
62
57
Overall Study
COMPLETED
55
46
Overall Study
NOT COMPLETED
7
11

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Efficacy of the Quell Wearable Device for Fibromyalgia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Total
n=119 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
57 Participants
n=99 Participants
52 Participants
n=107 Participants
109 Participants
n=206 Participants
Age, Categorical
>=65 years
5 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
Age, Continuous
48.3 years
STANDARD_DEVIATION 13.1 • n=99 Participants
52.3 years
STANDARD_DEVIATION 13.8 • n=107 Participants
50.4 years
STANDARD_DEVIATION 13.5 • n=206 Participants
Sex: Female, Male
Female
58 Participants
n=99 Participants
53 Participants
n=107 Participants
111 Participants
n=206 Participants
Sex: Female, Male
Male
4 Participants
n=99 Participants
4 Participants
n=107 Participants
8 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
5 Participants
n=99 Participants
5 Participants
n=107 Participants
10 Participants
n=206 Participants
Race (NIH/OMB)
White
48 Participants
n=99 Participants
47 Participants
n=107 Participants
95 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
7 Participants
n=99 Participants
4 Participants
n=107 Participants
11 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
62 participants
n=99 Participants
57 participants
n=107 Participants
119 participants
n=206 Participants

PRIMARY outcome

Timeframe: 3 months

The questionnaire reflects a patient's belief about the efficacy of treatment. The Patients' Global Impression of Change (PGIC) is a 7-point scale (1-7) depicting a patient's rating of overall improvement. Patients rate their change as 1="very much improved," 2="much improved," 3="minimally improved," 4="no change," 5="minimally worse," 6="much worse," or 7="very much worse." Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Patients' Global Impression of Change
3.58 score on a scale
Interval 3.09 to 4.07
3.24 score on a scale
Interval 2.74 to 3.75

SECONDARY outcome

Timeframe: Baseline, 3 months

The Brief Pain Inventory assesses the severity of pain and its impact on functioning. Pain Severity Score is calculated by adding the scores for questions 2, 3, 4 and 5 and then dividing by 4. This gives a severity score out of 10 (0-10), where 0 means no pain and 10 is worst possible pain. Pain Interference Score is calculated by adding the scores for questions 8a, b, c, d, e, f and g and then dividing by 7. This gives an interference score out of 10 (0-10), where 0 means does not interfere and 10 means completely interferes. Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
The Brief Pain Inventory
5.8 score on a scale
Standard Deviation 1.6
5.5 score on a scale
Standard Deviation 1.5

SECONDARY outcome

Timeframe: Baseline, 3 months

The Revised Fibromyalgia Impact Questionnaire (FIQR) is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQR has 3 domains: function, overall impact and symptoms. FIQR has 21 individual questions and all questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst'. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three domain scores. The total score of the FIQR ranges from 0 to 100. Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Revised Fibromyalgia Impact Questionnaire
61.3 score on a scale
Standard Deviation 16.3
52.8 score on a scale
Standard Deviation 17.3

SECONDARY outcome

Timeframe: Baseline, 3 months

The Pain Catastrophizing Scale (PCS) instructions ask participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The total score is computed by summing responses to all 13 items (scale 0-4). PCS total scores range from 0 - 52. The higher the score, the more catastrophizing thoughts are present. Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Pain Catastrophizing Scale
21.5 score on a scale
Standard Deviation 13.2
17.8 score on a scale
Standard Deviation 12.3

SECONDARY outcome

Timeframe: Baseline, 3 months

The Pain Disability Index is a simple and rapid instrument for measuring the impact that pain has on the ability of a person to participate in essential life activities. The total score is a sum of all 7 categories of life activity listed. A score of 0 means no disability at all, and a score of 10 signifies that all of the activities in which people would normally be involved have been totally disrupted or prevented by the pain. The total index ranges from 0 to 70. The higher the index the greater the person's disability due to pain. Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Pain Disability Index
39.4 score on a scale
Standard Deviation 15.6
34.6 score on a scale
Standard Deviation 15.5

SECONDARY outcome

Timeframe: Baseline, 3 months

The Hospital Anxiety and Depression Scale (HADS) was developed to assess depression and anxiety in patients. Responses are rated on a scale from 0 to 3, with higher scores indicating higher severity. The ratings of the 14 items are summed to yield a total score (0 to 42), or for each subscale separately (0 to 21). 0 to 7 for normal or no anxiety/depression, 8 to 10 for mild, 11 to 14 for moderate, and 12 to 21 for severe anxiety/depression. Lower values represent a better outcome.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Hospital Anxiety and Depression Scale
18.5 score on a scale
Standard Deviation 7.3
15.8 score on a scale
Standard Deviation 7.6

SECONDARY outcome

Timeframe: Post-treatment at 3 months

Self-report rating "How helpful was the TENS for your fibromyalgia?" 0=not at all helpful, 10=very helpful.

Outcome measures

Outcome measures
Measure
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices. Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
Helpfulness Rating
4.8 score on a scale
Standard Deviation 3.5
4.8 score on a scale
Standard Deviation 2.6

Adverse Events

High Frequency Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Low Frequency Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Robert Jamison

Brigham and Women's Hospital

Phone: 617-732-9046

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place